

TARGETED NUCLEIC ACID EDITING VIA CAS9-DEAMINASE FUSION PROTEINS

Tech ID: 34871 / UC Case 2015-054-0

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	10,392,607	08/27/2019	2015-054

BRIEF DESCRIPTION

Traditional genome editing relying on double-stranded DNA breaks (DSBs) can cause unintended indels, translocation events, and cytotoxic responses in target cells. To overcome these limitations, a precise site-specific modification technology is required that operates without inducing double-stranded DNA cleavage. Developed by UC Berkeley researchers, this technology utilizes engineered fusion proteins comprising a Cas domain (such as a Cas9 nickase or dCas9) integrated with a nucleic acid-editing enzyme domain, such as a deaminase. The molecular mechanism leverages the RNA-guided targeted binding capability of Cas9 to localize the enzymatic editing domain to a specific genomic locus, facilitating direct nucleotide alterations (e.g., cytidine or adenosine conversions) without introducing double-stranded cuts. This system delivers high-precision target modification, significantly reduces off-target insertion/deletion mutations, and improves cell viability during genomic modifications compared to conventional double-strand cleavage mechanisms.

SUGGESTED USES

»

Gene therapy for therapeutic correction of single-nucleotide genetic disorders in human cells

»

Functional genomics and targeted gene disruption or regulation in biomedical research

»

Development of genetically engineered crop varieties with specific agronomic traits

»

Generation of cellular and animal disease models for high-throughput therapeutic screening

ADVANTAGES

»

Enables precise nucleotide modification without introducing double-stranded DNA breaks

»

Significantly lower rate of unintended insertion/deletion (indel) mutations relative to standard double-strand breaking enzymes

»

High site-specificity driven by programmable RNA-guided Cas domains

»

Broad applicability across eukaryotic, prokaryotic, and viral host systems

RELATED MATERIALS

CONTACT

Ellen S. Kats
ellenkats@berkeley.edu
tel: .



INVENTORS

» Doudna, Jennifer A.

OTHER INFORMATION

CATEGORIZED AS

» **Biotechnology**

» Health

» **Medical**

» Gene Therapy

» Research Tools

» **Research Tools**

» Nucleic Acids/DNA/RNA

RELATED CASES

2015-054-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS
- ▶ Genome Editing via LNP-Based Delivery of Efficient and Stable CRISPR-Cas Editors
- ▶ Tissue-Specific Genome Engineering Using CRISPR-Cas9
- ▶ Type III CRISPR-Cas System for Robust RNA Knockdown and Imaging in Eukaryotes
- ▶ Cas9 Variants With Altered DNA Cleaving Activity
- ▶ Cas12-mediated DNA Detection Reporter Molecules
- ▶ Improved guide RNA and Protein Design for CasX-based Gene Editing Platform
- ▶ Compositions and Methods for Delivering Molecular Cargo to Cells
- ▶ Cas13a/C2c2 - A Dual Function Programmable RNA Endoribonuclease
- ▶ Miniature Type VI CRISPR-Cas Systems and Methods of Use
- ▶ RNA-directed Cleavage and Modification of DNA using CasY (CRISPR-CasY)
- ▶ Generation of Chimeric RNA with Type III CRISPR-Cas
- ▶ CasX Nickase Designs, Tans Cleavage Designs & Structure
- ▶ In Vivo Gene Editing Of Tau Locus Via Liponanoparticle Delivery
- ▶ Methods and Compositions for Modifying a single stranded Target Nucleic Acid
- ▶ Genetically Encoded, Biologically Responsive, And Programmable Bispecific Aptames As Therapeutic Protein Degraders
- ▶ A Dual-RNA Guided CasZ Gene Editing Technology
- ▶ A Protein Inhibitor Of Cas9
- ▶ RNA-directed Cleavage and Modification of DNA using CasX (CRISPR-CasX)
- ▶ Compositions and Methods for Genome Editing
- ▶ IS110 and IS1111 Family RNA-Guided Transposons
- ▶ Variant Cas12a Protein Compositions and Methods of Use
- ▶ In Vitro and In Vivo Genome Editing by LNP Delivery of CRISPR Ribonucleoprotein
- ▶ CRISPR CASY COMPOSITIONS AND METHODS OF USE
- ▶ Single Conjugative Vector for Genome Editing by RNA-guided Transposition
- ▶ Improved Cas12a Proteins for Accurate and Efficient Genome Editing
- ▶ CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
- ▶ Compositions and Methods for VIPR-Based Nucleic Acid Targeting
- ▶ Selective Cell Elimination using RNA-guided Chromatin Shredding
- ▶ Methods Of Use Of Cas12L/CasLambda In Plants
- ▶ Type V CRISPR/CAS Effector Proteins for Cleaving ssDNA and Detecting Target DNA
- ▶ THERMOSTABLE RNA-GUIDED ENDONUCLEASES AND METHODS OF USE THEREOF (GeoCas9)
- ▶ Variant TnpB and wRNA Proteins
- ▶ Efficient Site-Specific Integration Of New Genetic Information Into Human Cells
- ▶ Class 2 CRISPR/Cas COMPOSITIONS AND METHODS OF USE
- ▶ Compositions and Methods of Use for Variant Csy4 Endoribonucleases
- ▶ Immune Cell-Mediated Intercellular Delivery Of Biomolecules
- ▶ Methods and Compositions for Controlling Gene Expression by RNA Processing



University of California, Berkeley Office of Technology Licensing
2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704
Tel: 510.643.7201 | Fax: 510.642.4566
<https://ipira.berkeley.edu/> | otl-feedback@lists.berkeley.edu
© 2026, The Regents of the University of California
[Terms of use](#) | [Privacy Notice](#)